Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access |
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc |
Journal website http://www.jofem.org |
Original Article
Volume 6, Number 3, June 2016, pages 75-79
Effects of the Switching From High-Purity Eicosapentaenoic Acid to Combination of Eicosapentaenoic Acid and Docosahexaenoic Acid on Metabolic Parameters: A Retrospective Longitudinal Study
Tables
Age (years) | 63.8 ± 16.4 |
Sex (male/female) | 21/15 |
Body height (cm) | 160.4 ± 9.8 |
Body weight (kg) | 66.2 ± 14.9 |
Body mass index (BMI) (kg/m2) | 26.3 ± 5.4 |
Patients taking anti-diabetic drugs (n) | 14 |
Patients taking anti-hypertensive drugs (n) | 19 |
Patients taking anti-platelet agents (n) | 9 |
Patients taking lipid modifying agents (n) | 35 |
Statins | 17 |
Ion-exchange resin | 2 |
Fibrates | 4 |
Ezetimibe | 12 |
Daily EPA dose before switching (mg/day) | Daily EPA dose after switching (mg/day) | n |
---|---|---|
600 | 930 | 1 |
600 | 1,860 | 1 |
900 | 930 | 4 |
1,200 | 930 | 1 |
1,800 | 930 | 8 |
1,800 | 1,860 | 17 |
2,700 | 930 | 2 |
2,700 | 1,860 | 1 |
n | Before | 2 months after | P value | |
---|---|---|---|---|
Body weight (kg) | 17 | 66.2 ± 16.7 | 66.6 ± 17.1 | 0.73 |
Total cholesterol (mg/dL) | 26 | 192 ± 36 | 192 ± 38 | 0.77 |
HDL-cholesterol (mg/dL) | 32 | 48 ± 14 | 49 ± 15 | 0.78 |
LDL-cholesterol (mg/dL) | 21 | 108 ± 36 | 109 ± 33 | 0.68 |
Triglyceride (mg/dL) | 34 | 180 ± 136 | 163 ± 102 | 0.23 |
Non-HDL-cholesterol (mg/dL) | 24 | 138 ± 29 | 141 ± 36 | 0.87 |
AST (IU/L) | 34 | 27 ± 17 | 28 ± 14 | 0.34 |
ALT (IU/L) | 32 | 31 ± 21 | 32 ± 22 | 0.35 |
HbA1c (%) | 29 | 6.4 ± 0.8 | 6.4 ± 0.7 | 0.22 |
n | Before | 2 months after | P value | |
---|---|---|---|---|
Body weight (kg) | 2 | 57.5 ± 6.5 | 57.9 ± 7.2 | 0.69 |
Total cholesterol (mg/dL) | 6 | 199 ± 23 | 198 ± 31 | 0.87 |
HDL-cholesterol (mg/dL) | 6 | 52 ± 10 | 53 ± 10 | 0.80 |
LDL-cholesterol (mg/dL) | 6 | 118 ± 43 | 120 ± 45 | 0.85 |
Triglyceride (mg/dL) | 7 | 191 ± 196 | 146 ± 101 | 0.41 |
Non-HDL-cholesterol (mg/dL) | 5 | 142 ± 29 | 148 ± 41 | 0.73 |
AST (IU/L) | 7 | 30 ± 27 | 34 ± 30 | 0.53 |
ALT (IU/L) | 7 | 36 ± 30 | 34 ± 30 | 0.47 |
HbA1c (%) | 4 | 6.2 ± 0.5 | 6.2 ± 0.5 | 0.49 |
n | Before | 2 months after | P value | |
---|---|---|---|---|
Body weight (kg) | 12 | 57.5 ± 6.5 | 57.9 ± 7.2 | 0.69 |
Total cholesterol (mg/dL) | 15 | 199 ± 23 | 198 ± 31 | 0.87 |
HDL-cholesterol (mg/dL) | 15 | 52 ± 10 | 53 ± 10 | 0.80 |
LDL-cholesterol (mg/dL) | 11 | 118 ± 43 | 120 ± 45 | 0.85 |
Triglyceride (mg/dL) | 22 | 176 ± 119 | 159 ± 101 | 0.22 |
Non-HDL-cholesterol (mg/dL) | 15 | 142 ± 29 | 148 ± 41 | 0.73 |
AST (IU/L) | 21 | 30 ± 27 | 34 ± 30 | 0.53 |
ALT (IU/L) | 21 | 36 ± 30 | 34 ± 30 | 0.47 |
HbA1c (%) | 21 | 6.2 ± 0.5 | 6.2 ± 0.5 | 0.49 |
n | TG decreased | TG increased and TG did not change | P value | |
---|---|---|---|---|
All patients | 34 | 214 ± 152 (n = 22) | 119 ± 51 (n = 12) | 0.051 |
Patients underwent the switching to the formulation including half dose of EPA and DHA (EPA → half EPA + DHA) | 8 | 191 ± 214 (n = 6) | 127 ± 42 (n = 2) | 0.729 |
Patients underwent the switching to the formation including the same daily dose of EPA and DHA (EPA → same EPA + DHA) | 21 | 212 ± 129 (n = 14) | 103 ± 25 (n = 7) | 0.049 |
n | Before | 2 months after | P value | |
---|---|---|---|---|
All patients | 34 | |||
TG ≥ 150 mg/dL | 14 | 298 ± 140 | 249 ± 91 | 0.096 |
TG < 150 mg/dL | 20 | 99 ± 24 | 104 ± 54 | 0.722 |
EPA → half EPA + DHA | 8 | |||
TG ≥ 150 mg/dL | 2 | 417 ± 248 | 273 ± 80 | 0.549 |
TG < 150 mg/dL | 5 | 101 ± 23 | 97 ± 54 | 0.907 |
EPA → same EPA + DHA | 21 | |||
TG ≥ 150 mg/dL | 8 | 297 ± 114 | 239 ± 107 | 0.009 |
TG < 150 mg/dL | 13 | 102 ± 20 | 110 ± 56 | 0.673 |